Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047770 · ClinicalTrials.gov registry record · Phase 3
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,013
- Enrollment target
NCT05047770: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT05047770 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,013 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (161% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05047770, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,013 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.
Primary Outcome
Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and expressed as GMCs in milli-international units per milliliter (mIU/mL).
Interventions
- BIOLOGICAL mRNA-1273
- BIOLOGICAL HZ/su
- COMBINATION_PRODUCT Flu D-QIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,013 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 3 |
What the finished NCT05047770 record still lists
NCT05047770 is an interventional study that assigns participants to a tested intervention. Its 2,013 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (161% higher).
The record links to 0 conditions, and to 3 interventions - of which mRNA-1273 is the first listed.
NCT05047770 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05047770 about?
NCT05047770 is a clinical study titled "A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine". The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, ...
What is the current status of trial NCT05047770?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,013 participants. The study started on 2021-10-07. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT05047770?
The interventions under investigation include: mRNA-1273 (BIOLOGICAL), HZ/su (BIOLOGICAL), Flu D-QIV (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05047770?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05047770's enrollment target sits among peer trials
2,013 100th of 2000 higher than 1,901 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI